Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth emerged [6].

Enphase Energy, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 20, 2026 to Discuss Your Rights - ENPH [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Enphase Energy, Inc. ("Enphase Energy, Inc." or the "Company") (NASDAQ: ENPH) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Enphase Energy, Inc. investors who were adversely affected b ...

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Shareholder rights firm Levi & Korsinsky, LLP is investigating potential securities law violations by Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and reminds investors of the March 16, 2026 deadline to seek lead plaintiff status. THE INVESTIGATION: The firm is examining whether Vistagen and certain officers made false or misleading statements during the period from April 1, 2024 through December 16, 2025. ...

PayPal Investigation Focuses on Key Performance Metric Disclosures Amid 17% Stock Decline [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating PayPal Holdings, Inc. (NASDAQ: PYPL) regarding potential disclosure concerns related to the company's key operating metrics and the timing of information provided to investors. [Shareholders who suffered losses may obtain information about this investigation by clicking here.]The SEC has issued guidan ...

Class Action Filed Against Fermi Inc. (FRMI) - March 6, 2026 Deadline to Join - Contact Levi & Korsinsky [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and e ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 clinical trial [5][6]. - The defendants made positive assertions about the drug's trial success based on previous results, which the lawsuit claims were misleading [5].

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. (AGL) for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by March 2, 2026 [1] Summary by Relevant Sections Legal Action - A federal securities class action has been filed against agilon health, alleging that the company and its executives made false and misleading statements regarding their financial guidance and business operations [1] - The complaint claims that the defendants issued guidance for 2025 that they knew or should have known was unattainable due to industry headwinds [1] - The lawsuit also alleges that the defendants overstated the financial impact of strategic actions taken to reduce risk, leading to materially false statements about the company's prospects [1] Financial Impact - On August 4, 2025, agilon health reported its second-quarter results, indicating that industry challenges were more severe than previously anticipated, and subsequently suspended its full-year 2025 financial guidance [1] - Following this announcement, agilon health's stock price dropped by 51.5% on August 5, 2025, reflecting the market's reaction to the revised outlook [1] Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the group [1] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member, with their ability to recover not affected by this decision [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status set for April 7, 2026 [1] Group 1: Allegations Against Inovio Pharmaceuticals - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device [1] - It is claimed that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 due to these deficiencies [1] - The company reportedly lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [1] Group 2: Impact on Stock Price - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [1] Group 3: Legal Proceedings and Investor Actions - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, overseeing the litigation on behalf of the class [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1]

Core Viewpoint - A securities class action has been filed against Vistagen Therapeutics, Inc. for alleged violations of federal securities laws, specifically related to misleading statements and omissions during a defined period [1] Legal Claims - The complaint asserts claims under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5, which prohibits materially false or misleading statements in securities transactions [1] - Section 20(a) holds controlling persons liable for the conduct of those primarily liable [1] Class Definition - The class includes all individuals and entities that purchased Vistagen common stock from April 1, 2024, to December 16, 2025, and suffered damages upon the revelation of alleged corrective disclosures [1] - Exclusions from the class include defendants, company officers and directors, their immediate family members, and legal representatives [1] PSLRA Procedures - Under the Private Securities Litigation Reform Act of 1995, class members can seek to serve as lead plaintiff by filing a motion with the court by March 16, 2026 [1] - The lead plaintiff will manage the litigation on behalf of the class, and participation in any recovery is not affected by the decision to serve as lead plaintiff [1] About the Law Firm - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [1] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [1]